左西孟旦治疗心力衰竭的研究进展

Research progress in the treatment of heart failure with levosimontan

心力衰竭的特点是心输出量减少,导致外周灌注不足和肺充血,并可导致急性肺水肿的发展.治疗失代偿性心力衰竭患者的主要目标是稳定血流动力学,这通常需要通过正性肌力支持来实现.经典正性肌力药物可短期内改善血流动力学,但往往会导致不良预后发生.左西孟旦是一种新型钙增敏剂,可在不增加cAMP和细胞内钙浓度的情况下改善血液动力学和症状.该药物可改善收缩力,而不会增加心律失常等心脏事件的风险.此研究旨在通过分析国内外近几年有关左西孟旦的研究进展,为该药在心力衰竭中的应用提供参考.

Heart failure is characterized by a decrease in cardiac output,leading to insufficient peripheral perfusion and pulmonary congestion,and can lead to the development of acute pulmonary edema.The main goal of treating patients with decompensated heart failure is to stabilize hemodynamics,which usually requires positive muscle strength support.Classic positive inotropic drugs can provide short-term hemodynamic improvements,but their use is associated with poor prognosis.Levosimontan is a novel calcium sensitizer that can improve hemodynamics and symptoms without increasing cAMP and intracellular calcium concentrations.The drug can improve contractility without increasing the risk of cardiac events such as arrhythmia.This study aims to provide reference for the application of levosimontan in heart failure by analyzing the research progress of levosimontan at home and abroad in recent years.